You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》麦格理降丽珠医药(01513.HK)评级至「中性」 目标价下调至30.1元
阿思达克 06-02 10:04
麦格理在研究报告中指出,丽珠医药(01513.HK)近年研发部门频繁出现人事变动,或影响产品上市进度,将其投资评级由「跑赢大市」降至「中性」,以反映中期前景疫弱。

丽珠医药日前公布,去年加盟集团、接替傅道田负责丽珠单抗公司的戴卫国,已於上月底辞任。麦格理指出,频繁的人事变动将令公司研究工作难度增加,预期要到2024年才可推出创新的新产品,大大落後同业。

该行指,丽珠医药首季表现符合预期,核心盈利增长22.6%,期内收入则按年跌4%。预料在疫情下,公司的诊断业务将成为主要增长动力,额外为全年销售额贡献7.5亿元人民币。麦格理调整2021及2022年每股盈利预测,分别上调3%及下调7%,并将目标价由39.1元下调至30.1元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account